Latest News
April 14th, 2025
How Can Nutritionists and Psychiatrists Collaborate?
Patient outcomes improve when nutritionists and psychiatrists collaborate.
April 1st, 2025
Talking About New Perspectives
Frank A. Clark, MD, talks about his new series on Psychiatric Times.
February 21st, 2019
What Makes Binge Eating Such a Prevalent Issue?
Carlos M. Grilo, PhD, discusses why binge eating disorder is such a widespread issue.
February 21st, 2019
What is the relationship between bacteria in the gut and psychiatric disorders?
Douglass Drossman, MD, discusses the relationship between bacteria in the gut, causing illness, and psychiatric disorders.
All News
August 29th, 2022
Eisenhower Fellowships Launches 2022 USA Justice Program With Psychiatric Fellow
Eisenhower Fellowships has launched its 2022 USA Justice Program with an inaugural cohort of 11 mid-career US professionals from a variety of fields, including psychiatry, to address issues in inequality.
August 22nd, 2022
Virtual Psychiatry is Here to Stay
One psychiatrist considers the advantages of virtual psychiatric treatment for both patients and clinicians.
August 17th, 2022
Trauma in Your DNA: Educator of the Year Lecture
Real true, posttraumatic stress disorder [PTSD] is going to have an impact, certainly on the next generation and maybe generations after that," said Rachel Yehuda, PhD.
March 7th, 2019
FDA Announces Approval of Esketamine Nasal Spray For Treatment of Drug Resistant Major Depressive Disorder
In an overwhelming approval the FDA approved the use of Esketamine nasal spary, known as <em>SPRAVATO™, </em>for the treatment of drug resistant major depressive disorder. A major step for those that support the use of ketamine in the treatment of depression.
February 22nd, 2019
Rare Genetic Variants Implicated in the Development of Schizophrenia
Rare genetic variants can have an effect on the N-methyl-D-aspartate receptor that carries brain signals between brain cells in response to glutamate. A recent study on the receptor revealed these genetic variants might have an implication on the development of Schizophrenia.
February 20th, 2019
FDA Reclassifies Electroconvulsive Therapy Devices to Lower Risk Category
Electroconvulsive Therapy Devices have varying uses due to their complicated benefits and risks. The FDA recently recgonized this and now ECT devices have been reclassfied.
February 20th, 2019
SPN-812 Gains A Third Positive Study for the Treatment of Adolescents with ADHD
In its third Phase III study, SPN-812 met its primary endpoint with positive results. Marking a major step for Supernus Pharmaceuticals novel ADHD treatment.<br />
<br />
February 5th, 2019
Study Finds a Higher Risk of Bipolar Disorder in Patients with SYNE1 Gene Mutations
Researchers from the Picower Institute for Learning and Memory at MIT have found a link between SYNE1 Gene Mutations and the expression of CPG2 protein. Which is linked to having bipolar disorder. <br />
February 5th, 2019
Axsome Therapeutics AXS-05 Meets Primary Endpoint in Phase 2 Trial for Major Depressive Disorder Treatment
Axsome Therapeutics recently announced that its novel drug AXS-05 met its primary endpoints in a Phase 2 trial, that could see the drug have a major positive impact on the major depressive disorder population. <br />
Advertisement
Advertisement
